CN1564686A - 8－氨基－[1,2,4]三唑并[1,5－a]吡啶－6－甲酰胺 - Google Patents

8－氨基－[1,2,4]三唑并[1,5－a]吡啶－6－甲酰胺 Download PDF

Info

Publication number
CN1564686A
CN1564686A CNA02819912XA CN02819912A CN1564686A CN 1564686 A CN1564686 A CN 1564686A CN A02819912X A CNA02819912X A CN A02819912XA CN 02819912 A CN02819912 A CN 02819912A CN 1564686 A CN1564686 A CN 1564686A
Authority
CN
China
Prior art keywords
amino
furan
pyridine
triazol
chemical compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA02819912XA
Other languages
English (en)
Chinese (zh)
Inventor
M·H·内特科文
S·施米特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1564686A publication Critical patent/CN1564686A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA02819912XA 2001-10-08 2002-10-04 8－氨基－[1,2,4]三唑并[1,5－a]吡啶－6－甲酰胺 Pending CN1564686A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01123948 2001-10-08
EP01123948.0 2001-10-08

Publications (1)

Publication Number Publication Date
CN1564686A true CN1564686A (zh) 2005-01-12

Family

ID=8178876

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA02819912XA Pending CN1564686A (zh) 2001-10-08 2002-10-04 8－氨基－[1,2,4]三唑并[1,5－a]吡啶－6－甲酰胺

Country Status (13)

Country Link
US (1) US6689790B2 (enExample)
EP (1) EP1435952A1 (enExample)
JP (1) JP4101755B2 (enExample)
KR (1) KR100614486B1 (enExample)
CN (1) CN1564686A (enExample)
AR (1) AR036734A1 (enExample)
AU (1) AU2002347055B2 (enExample)
BR (1) BR0213172A (enExample)
CA (1) CA2462806A1 (enExample)
MX (1) MXPA04003277A (enExample)
PL (1) PL370067A1 (enExample)
RU (1) RU2296763C2 (enExample)
WO (1) WO2003030904A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102471337A (zh) * 2009-07-17 2012-05-23 日本烟草产业株式会社 三唑并吡啶化合物及其作为脯氨酰基羟化酶抑制剂和红细胞生成素产生诱导剂的作用
CN104370807A (zh) * 2014-11-13 2015-02-25 安徽星宇化工有限公司 一种6-羟基-5-硝基烟酸的合成方法及其分离提纯方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2288260A4 (en) * 2008-06-20 2013-10-23 Genentech Inc TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD
EP2296475A4 (en) * 2008-06-20 2014-03-05 Genentech Inc TRIAZOLOPYRIDINE COMPOUNDS JAK KINASE INHIBITORS AND METHODS
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
RU2620379C2 (ru) * 2012-02-09 2017-05-25 Ф.Хоффманн-Ля Рош Аг СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 2-ФЕНИЛ[1,2,4]ТРИАЗОЛО[1,5-а]ПИРИДИНА
US9048427B2 (en) * 2013-03-06 2015-06-02 National Tsing Hua University Thin film fabrication of rubber material with piezoelectric characteristics
BR112015029899B1 (pt) * 2013-05-31 2020-07-21 Nissan Chemical Corporation composto de amida heterocíclica e sal do mesmo da formula (1), produto quimico agrícola e herbicida obtido
MX2020010618A (es) 2018-04-08 2020-11-12 Beigene Ltd Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法
WO2020054712A1 (ja) * 2018-09-12 2020-03-19 日本化薬株式会社 有害生物防除剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE287263C (enExample) *
HU208693B (en) * 1991-02-22 1993-12-28 Egyt Gyogyszervegyeszeti Gyar Process for producing 1,2,4-triazolo (1,5-a) pyrimidinis derivatives and their carbicycli-tetrahydro-thiofurane-tetrahydrothiopyrane-, or tetrahydropyridine- condensated derivatives or medical preparatives containing them
EP0765327B1 (en) * 1994-06-16 1999-07-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
AU743910B2 (en) * 1997-03-24 2002-02-07 Kyowa Hakko Kirin Co., Ltd. {1,2,4}triazolo{1,5-c}pyrimidine derivatives
US6355653B1 (en) * 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6506772B1 (en) * 2000-12-15 2003-01-14 Hoffmann-La Roche Inc. Substituted [1,2,4]triazolo[1,5a]pyridine derivatives with activity as adenosine receptor ligands

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102471337A (zh) * 2009-07-17 2012-05-23 日本烟草产业株式会社 三唑并吡啶化合物及其作为脯氨酰基羟化酶抑制剂和红细胞生成素产生诱导剂的作用
CN104370807A (zh) * 2014-11-13 2015-02-25 安徽星宇化工有限公司 一种6-羟基-5-硝基烟酸的合成方法及其分离提纯方法

Also Published As

Publication number Publication date
AR036734A1 (es) 2004-09-29
US6689790B2 (en) 2004-02-10
RU2296763C2 (ru) 2007-04-10
KR20040048940A (ko) 2004-06-10
JP2005508942A (ja) 2005-04-07
US20030207911A1 (en) 2003-11-06
BR0213172A (pt) 2004-09-14
KR100614486B1 (ko) 2006-08-22
AU2002347055B2 (en) 2006-10-12
CA2462806A1 (en) 2003-04-17
RU2004114278A (ru) 2005-10-27
MXPA04003277A (es) 2004-07-23
WO2003030904A1 (en) 2003-04-17
JP4101755B2 (ja) 2008-06-18
PL370067A1 (en) 2005-05-16
EP1435952A1 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
CN1264840C (zh) 8－甲氧基－(1,2,4)三唑并(1,5－a)吡啶衍生物及其作为腺苷受体配体的应用
CN1731999A (zh) 苯并噻唑衍生物
CN100346792C (zh) 用作腺苷受体配体的苯并噻唑衍生物
US20040229893A1 (en) Substituted benzothiazole amide derivatives
CN1451007A (zh) 腺苷A2a受体拮抗剂
CN1684964A (zh) 一些新的咪唑并吡啶及其用途
CN1692116A (zh) 腺苷A2a受体拮抗剂
CN1564686A (zh) 8－氨基－[1,2,4]三唑并[1,5－a]吡啶－6－甲酰胺
CN1956983A (zh) 4－羟基－4－甲基－哌啶－1－甲酸(4－甲氧基－7－吗啉－4－基－苯并噻唑－2－基)－酰胺
CN1823062A (zh) 作为5－羟色胺－6配体的磺酰基二氢苯并咪唑酮化合物
CN1254475C (zh) 用作腺苷受体拮抗剂的5－甲氧基－8－芳基－[1,2,4]三唑并[1,5－a]吡啶衍生物
CN1726213A (zh) 作为腺苷a3受体配体的咪唑并喹啉衍生物
US7371749B2 (en) Benzothiazole derivatives
US6506772B1 (en) Substituted [1,2,4]triazolo[1,5a]pyridine derivatives with activity as adenosine receptor ligands
CN1596112A (zh) 苯并噻唑衍生物
AU2002347055A1 (en) Substituted Triazolopyridine Compounds
CN1780831A (zh) 作为腺苷受体配体的2－咪唑－苯并噻唑
CN1791405A (zh) 苯并噻唑衍生物及其在治疗涉及腺苷a 2a受体的疾病中的应用
JP4426572B2 (ja) ベンゾチアゾール誘導体、およびアデノシンａ２ａ受容体に関連した疾患の処置でのその使用
CN1723204A (zh) 苯并噁唑衍生物及其作为腺苷受体配体的用途
CN1791600A (zh) 用作腺苷受体的配体的苯并噻唑衍生物
KR100700422B1 (ko) 아데노신 수용체 리간드로서의7-([1,4]다이옥산-2-일)-벤조티아졸 유도체
CN1296368C (zh) 用作腺苷受体调节剂的苯并噻吩化合物
HK1093021A (en) Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine a2a receptor
HK1092469B (en) Benzothiazole derivatives as adenosine receptor ligands

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication